Qiagen NV (NYSE:QGEN)
$ 46.06 -0.1 (-0.22%) Market Cap: 10.26 Bil Enterprise Value: 10.70 Bil PE Ratio: 113.42 PB Ratio: 2.91 GF Score: 87/100

Qiagen NV at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 03:15PM GMT
Release Date Price: $46.6 (+0.13%)
Luke England Sergott
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everybody. I'm Luke Sergott from Life Science Tools Diagnostics here at Barclays. With me, it's a pleasure to have Roland Sackers and John Gilardi of QIAGEN. It's been a long time, good to see you in person. So with that, if you guys want to open with a little comments, then we can dig in.

Roland Sackers
QIAGEN N.V. - CFO, MD & Member of Management Board

Yes, why not. And again, thanks for having us and also for us, I think the first physical conference, at least in the U.S. for quite some while. It's good to be back. I thought (inaudible) but again. Yes, I think it's good to be -- and also good to report out on some of the developments we see. And as you know, we put out a very good fiscal year '21, clearly had a strong performance, actually both overall, what we call COVID-related business, which I think is probably more important for us also very strong performance of the non-COVID side, we have seen now, I think, consecutive quarters where we were able not only

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot